65 related articles for article (PubMed ID: 34254358)
1. Participation in ENSEMBLE phase III multicenter clinical trial of Ad26.CoV2.S, a COVID-19 vaccine: An investigational drug services perspective.
Li N
J Clin Pharm Ther; 2022 Mar; 47(3):360-362. PubMed ID: 34254358
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
[TBL] [Abstract][Full Text] [Related]
4. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
5. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
7. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
[TBL] [Abstract][Full Text] [Related]
8. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
[TBL] [Abstract][Full Text] [Related]
10. Massive bullous local reaction following administration of Ad26.COV2.S COVID-19 vaccine.
Montero-Menárguez J; Falkenhain-López D; Guzmán-Pérez LM; Rodríguez-Peralto JL; Tous-Romero F; Gallego-Álvarez S
Int J Dermatol; 2022 May; 61(5):636-638. PubMed ID: 35049059
[No Abstract] [Full Text] [Related]
11. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
[TBL] [Abstract][Full Text] [Related]
12. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
[TBL] [Abstract][Full Text] [Related]
13. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.
Botton J; Semenzato L; Jabagi MJ; Baricault B; Weill A; Dray-Spira R; Zureik M
JAMA Netw Open; 2022 Mar; 5(3):e220868. PubMed ID: 35234883
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
[TBL] [Abstract][Full Text] [Related]
16. Single-Dose Ad26.COV2.S Vaccine-Room for Improvement.
Tehrani ZR; Sajadi MM
JAMA Netw Open; 2021 Nov; 4(11):e2133012. PubMed ID: 34726751
[No Abstract] [Full Text] [Related]
17. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination.
Charidimou A; Samudrala S; Cervantes-Arslanian AM; Sloan JM; Dasenbrock HH; Daneshmand A
J Stroke Cerebrovasc Dis; 2021 Dec; 30(12):106113. PubMed ID: 34547677
[No Abstract] [Full Text] [Related]
18. Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome.
Li HF; Hu SM; Lv M
JAMA; 2022 Jan; 327(4):392-393. PubMed ID: 35076675
[No Abstract] [Full Text] [Related]
19. Efficacy of COVID-19 vaccines in patients taking immunosuppressants.
Shen C; Risk M; Schiopu E; Hayek SS; Xie T; Holevinski L; Akin C; Freed G; Zhao L
Ann Rheum Dis; 2022 Jun; 81(6):875-880. PubMed ID: 35197265
[TBL] [Abstract][Full Text] [Related]
20. Comment on "Oral lichen planus following the administration of vector based COVID-19 vaccine (Ad26.COV2.S)". Authors' reply.
Troeltzsch M; Berndt R; Troeltzsch M
Oral Dis; 2022 Nov; 28 Suppl 2():2610-2611. PubMed ID: 34704310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
